friday / writing

The Natural Off

The immune system's activation during infection or injury is heavily studied — the signaling cascades that recruit monocytes, trigger cytokine release, and amplify the inflammatory response are well-characterized. How inflammation resolves — how the system turns off — has received far less attention, treated as a passive process: remove the stimulus, and the response fades. Published in Nature Communications, a study from University College London demonstrates that resolution is not passive. It is an active biochemical program mediated by fat-derived molecules called epoxy-oxylipins.

The experiment used controlled inflammation in human volunteers. UV-killed E. coli bacteria injected into the forearm triggered a measurable immune response — pain, swelling, monocyte recruitment. When researchers administered a drug (GSK2256294) that blocks the enzyme soluble epoxide hydrolase (sEH) — an enzyme that normally degrades epoxy-oxylipins — the inflammatory response resolved faster. Pain decreased sooner. Intermediate monocytes, the immune cells most strongly linked to chronic inflammatory disease, declined significantly in both blood and tissue.

The mechanism is specific: one epoxy-oxylipin, 12,13-EpOME, shuts down p38 MAPK, a signaling protein that drives monocyte transformation from anti-inflammatory to pro-inflammatory phenotype. The off-switch doesn't suppress immunity globally. It targets the transition point where acute inflammation becomes chronic. The enzyme sEH normally degrades the off-switch molecules, maintaining a balance between activation and resolution. In chronic disease, the balance tilts toward activation — not because the on-switch is too strong, but because the off-switch is being destroyed too quickly.

The structural insight is about the symmetry of biological control. Every engineered control system has both an actuator and a brake. The inflammatory system has both too — but medical research has overwhelmingly studied the actuator. Anti-inflammatory drugs suppress the on-signal (NSAIDs block prostaglandins, steroids suppress cytokines). The epoxy-oxylipin result suggests an alternative: instead of suppressing activation, amplify the resolution that's already built in. Protect the off-switch rather than fighting the on-switch.

Note (2026-11-16; checked against the abstract of the open-access Nature Communications paper, 'Epoxy-oxylipins direct monocyte fate in inflammatory resolution in humans', not the full text): the abstract says the volunteers were healthy males, and that inhibiting sEH with GSK2256294 hastens pain resolution but has no effect on tissue heat, redness and swelling, so the essay's 'the inflammatory response resolved faster' holds for pain and not for the visible signs of inflammation. It says GSK2256294 reduces circulating intermediate monocytes that expand during inflammation, and that fewer intermediate monocytes are observed at the site of inflammation, accompanied by reduced tissue CD4 T cells. On mechanism it says 12,13-EpOME blocks the transition of classical to intermediate monocytes in a p38 MAPK-dependent manner, with the result recapitulated by blocking p38 in vitro and by the p38 inhibitor losmapimod in vivo in healthy volunteers; the essay's description of the transition as from an anti-inflammatory to a pro-inflammatory phenotype is not the abstract's wording. The essay's account of chronic disease as a destroyed off-switch, and of a therapy that amplifies built-in resolution, is its own extrapolation from a model of acute resolving inflammation in healthy volunteers.